NASDAQ · Key Statistics

Retension Pharmaceuticals Inc. (RTSN) P/E Ratio, ROE & Key Statistics

$11.41 NASDAQ: RTSN Market Cap $42.79M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Retension Pharmaceuticals Inc. (RTSN), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-5.16
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-18.55%

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.0.00%
Operating marginRevenue left after operating costs.0.00%
Net marginRevenue left after every cost, including tax and interest.0.00%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.5.61
Quick ratioThe same, excluding inventory.4.69

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$2.78
Book value per shareShareholders’ equity divided by shares outstanding.−$18.48
Market capitalisationShare price times shares outstanding.$42.79M

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Retension Pharmaceuticals Inc. (RTSN) statistics — frequently asked questions

What is Retension Pharmaceuticals Inc.'s P/E ratio?

Retension Pharmaceuticals Inc. (RTSN) trades on a price-to-earnings ratio of -5.16. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

How much debt does Retension Pharmaceuticals Inc. carry?

Retension Pharmaceuticals Inc. (RTSN) has a debt-to-equity ratio of 0.00, which compares total borrowings with shareholders' equity.

P/E and ROE of other Medical - Pharmaceuticals stocks

RPRX P/E 41.25CORT P/E 49.69LQDA key statisticsPBH P/E 13.90QUIT ROE -225.39%HITI ROE -36.06%ETRA key statisticsTRXB ROE -53.14%NSRX ROE -158.83%All Medical - Pharmaceuticals stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.